Malignant lymphomas of the nasal cavity and paranasal sinuses. A clinicopathologic and immunohistochemical study.
The clinicopathologic and immunohistological features of 20 Japanese patients with non-Hodgkin's lymphomas (NHLs) limited to the sinonasal area were studied using a broad panel of T- and B-cell markers on paraffin-embedded and fresh frozen tissue. All cases showed a diffuse growth pattern. Nine cases were B-cell lymphomas (immunoblastic n = 4, centroblastic n = 3, immunocytoma n = 1, centrocytic n = 1), and nine were T-cell lymphomas (pleomorphic medium and large cell n = 8, angioimmunoblastic n = 1). In two cases, the cell lineage could not be determined. No morphologic features of angiocentric/angiodestructive lymphoproliferative lesions or lymphoepithelial lesions in ductal or glandular epithelium were seen in our series. Eight (89%) of the nine T-cell tumors and four (44%) of the nine B-cell neoplasms involved both the nasal cavity and paranasal sinuses. Six of the nine T-cell neoplasms showed a clinical presentation of rhinitis, whereas all of the B-cell neoplasms showed tumor masses in the nasal cavity and/or paranasal sinuses. The two-year survival rate for T-cell lymphomas was poorer than that for B-cell lymphomas. The five-year survival of patients with NHLs involving both the nasal cavity and paranasal sinuses was also poorer than that of patients in whom NHLs were limited to the nasal cavity.
Kojima
M
M
Department of Pathology, Ashikaga Red Cross Hospital, Japan.
Hosomura
Y
Y
Kurabayashi
Y
Y
Ohno
Y
Y
Itoh
H
H
Yoshida
K
K
Johshita
T
T
Tamaki
Y
Y
Niibe
H
H
Nakamura
S
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D016130:Immunophenotyping; D016393:Lymphoma, B-Cell / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D016399:Lymphoma, T-Cell / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009296:Nasal Cavity / Q000473:pathology; D009669:Nose Neoplasms / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D010255:Paranasal Sinus Neoplasms / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D015996:Survival Rate